After Biosimilar Fee Collections Fall Short, US FDA Modifies Carryover Spend-Down Plan

 
• By Sue Sutter
Road_Slow
US FDA's plan for spending down its biosimilar user fee carryover balance unexpectedly accelerated in FY 2018, forcing the agency to readjust. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics